Diabetic foot ulcers represent one of the most challenging complications associated with diabetes. The loss of sensitivity due to peripheral neuropathy, a form of nerve damage, can result in individuals failing to notice injuries on their feet. Furthermore, the alterations linked to the disease hinder the healing of tissues. When wounds remain open for extended periods, they are prone to infection, and in severe cases, may necessitate amputation.
Innovative Stem Cell Therapy Trials
In response to the escalating challenges posed by diabetes globally, a team of researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) in the United States has conducted a pioneering trial of a placenta-derived stem cell therapy in humans. This study, recently published in Stem Cells Translational Medicine, primarily aimed to assess the safety of the procedure while also exploring its potential effects on wound healing, neuropathy, and blood flow in the foot.
The participants were recruited in Nicaragua, comprising ten individuals aged between 40 and 74 years who had ulcers that had not healed for at least three months despite conventional treatments. The wounds varied in size from 14 to 100 square centimetres, with some patients also experiencing tissue erosion and exposed tendons. The study includes graphic images of the ulcers, which may be distressing to some readers.
Processing and Administration of Stem Cells
The stem cells used in the trial were sourced from placentas obtained following normal deliveries from healthy women. These cells were processed, cultured, and subjected to various safety tests prior to their administration. Researchers employed three dosage levels, injecting the cells directly into the wound bed, around its perimeter, and along the arteries in the foot.
The initial safety outcomes were promising, with no severe adverse reactions reported among the patients during the 12-month follow-up period. While all volunteers experienced a sensation of swelling in the treated leg immediately after the injections, this effect subsided by the following day. Furthermore, there were no recorded infections, skin reactions, or bruising associated with the procedure.
Healing Outcomes and Sensory Recovery
Remarkably, two patients achieved complete closure of their ulcers within two months, while the remaining participants reached a similar outcome by the six-month mark. Even patients with exposed tendons managed to achieve full tissue coverage, retaining their range of motion, which was visually striking when comparing before and after images.
Moreover, the research indicated signs of potential sensory recovery. Tests conducted before the treatment and 12 months later revealed significant improvements in both touch perception and vibration sensitivity. According to the authors, all ten participants exhibited improvements in neuropathy, with nine achieving normal protective sensation within a year.
Circulatory Improvements and Future Research Directions
However, the results concerning blood circulation were less definitive. Some arteries showed increased blood flow, while others displayed a decrease. Notably, seven vessels that initially lacked detectable flow demonstrated measurable flow after 12 months, but the researchers concluded that the evidence does not yet support a definitive vascular benefit.
“This preliminary study was primarily designed to address a safety question,” stated Michael Carstens, co-author of the study. “Within the doses we evaluated, the cells were well tolerated, and we did not observe any serious adverse events related to the treatment during the 12-month follow-up.”
Cautions and Recommendations for Future Studies
Nevertheless, the authors caution that it would be premature to consider this therapy as a readily available treatment option for patients. The study involved only ten individuals with diabetic foot ulcers, lacked a control group, and was not conducted in a blinded manner. Therefore, the findings regarding efficacy primarily serve to generate hypotheses that must be validated in future studies involving larger patient cohorts, control groups, and extended follow-up periods. This approach will help to evaluate both the efficacy and long-term safety of the therapy.
“For individuals with diabetic nerve damage, the loss of sensitivity in the foot can make it difficult to detect an injury before it escalates into a serious wound,” explained Anthony Atala, the principal author of the study and director of WFIRM. “The improvements we observed in wound healing and in two different measures of sensitivity are encouraging, but further studies are necessary.”
